Loading clinical trials...
Loading clinical trials...
This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Peking University First Hospital
NCT06388967 · Pancreatic Cancer, Pancreatic Carcinoma, and more
NCT06937996 · Pancreatic Cancer Non-resectable
NCT06503497 · Pancreatic Cancer Non-resectable
NCT07326150 · Pancreatic Cancer Resectable, Pancreatic Cancer Non-resectable
NCT04986930 · Pancreatic Adenocarcinoma, Pancreatic Cancer Non-resectable
Department of Radiotherapy Oncology, Peking University First Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions